Zentalis Pharmaceuticals, Inc. Equity Securities, FV-NI
Zentalis Pharmaceuticals, Inc. (ZNTL) had Equity Securities, FV-NI of $0 as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:EquitySecuritiesFvNi · last filed 2026-03-26
- 2025-12-31: Equity Securities, FV-NI $0.00.
- 2025-09-30: Equity Securities, FV-NI $2.41M.
- 2025-06-30: Equity Securities, FV-NI $16.79M.
- 2025-03-31: Equity Securities, FV-NI $12.15M.
| Period end | Equity Securities, FV-NI |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-26 |
| 2025-09-30 | $2.41M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $16.79M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $12.15M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $19.17M 10-K · filed 2026-03-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |